美国急诊科肺栓塞诊断与管理的八年流行病学变化
该横断面研究利用Epic Cosmos全国数据库,纳入2016年1月1日至2023年12月31日急诊就诊并诊断为急性肺栓塞的患者,排除慢性肺栓塞,评估就诊量、入院率、急诊抗凝与溶栓治疗及CT肺动脉造影(CTPA)率的变化。在186,138,130次急诊就诊中,肺栓塞占531,968次(0.29%),诊断率从2016年0.20%缓慢升至2021年峰值0.35%;入院363,584例(68.3%),入院率由75.6%降至66.1%。抗凝以阿哌沙班最常见(40.0%),其次为利伐沙班(17.3%)、依诺肝素(6.1%)、华法林(2.6%)、达比加群(0.4%);溶栓占4.5%,2018年峰值5.3%,2023年降至3.5%;CTPA率由2.4%升至5.0%,而诊断为肺栓塞的比例由8.7%降至6.4%。
要点
- 2016至2023年急诊肺栓塞诊断率由0.20%升至2021年峰值0.35%,总急诊就诊186,138,130次中肺栓塞531,968次(0.29%)。
- 肺栓塞患者入院363,584例(68.3%),入院率由75.6%降至66.1%,更多患者从急诊离院。
- 急诊抗凝以阿哌沙班最常见(40.0%),其次利伐沙班17.3%、依诺肝素6.1%、华法林2.6%、达比加群0.4%。
- 溶栓治疗占4.5%,2018年峰值5.3%,2023年降至3.5%。
- CTPA率由2.4%升至5.0%,而诊断为肺栓塞的比例由8.7%降至6.4%。
适用人群与场景
- 2016年1月1日至2023年12月31日美国急诊科就诊并诊断为急性肺栓塞的患者,排除慢性肺栓塞。
诊断标准与关键阈值
- 采用ICD-10编码识别急性肺栓塞急诊就诊,排除慢性肺栓塞。
处置流程与药物剂量
- 急诊抗凝处方包括华法林、依诺肝素、达比加群、阿哌沙班、利伐沙班、艾多沙班和贝曲沙班;其中阿哌沙班40.0%、利伐沙班17.3%、依诺肝素6.1%、华法林2.6%、达比加群0.4%。
- 溶栓药物包括阿替普酶、替奈普酶和尿激酶,总体溶栓率4.5%,2018年峰值5.3%,2023年3.5%。
研究设计与关键结果
- 横断面研究,基于Epic Cosmos全国数据库,纳入2016年1月1日至2023年12月31日急诊就诊的急性肺栓塞患者,排除慢性肺栓塞,评估就诊量、入院率、抗凝与溶栓治疗及CTPA率变化。
- 总急诊就诊186,138,130次,肺栓塞531,968次(0.29%);诊断率从2016年0.20%缓慢升至2021年峰值0.35%。
- 肺栓塞患者入院363,584例(68.3%),入院率由75.6%降至66.1%。
- 抗凝药物以阿哌沙班最常见(40.0%),其次利伐沙班17.3%、依诺肝素6.1%、华法林2.6%、达比加群0.4%。
- 溶栓治疗占4.5%,2018年峰值5.3%,2023年降至3.5%。
- CTPA率由2.4%升至5.0%,诊断为肺栓塞的比例由8.7%降至6.4%。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Pulmonary embolism (PE) is a major cause of morbidity and mortality in the United States. However, as diagnostic imaging, risk stratification tools, and treatment have evolved over time, there is a critical need for current data on the incidence, testing, admission rates, and medical management of PE in the ED setting.
METHODS: This was a cross-sectional study of ED patients with PE diagnoses from 1/1/2016 to 12/31/2023 using the Epic Cosmos national database. ED visits were identified using ICD-10 codes corresponding to acute PE. Chronic PEs were excluded. Outcomes included total ED visits, admission rates, anticoagulant treatment prescribed from the ED, and thrombolytic therapy. Anticoagulant prescriptions included warfarin, enoxaparin, dabigatran, apixaban, rivaroxaban, edoxaban, and betrixaban. Thrombolytic agents included alteplase, tenecteplase, and urokinase. We also assessed changes in the overall rate of CT pulmonary angiograms (CTPA) performed.
RESULTS: Out of 186,138,130 total ED encounters, PE represented 531,968 (0.29 %). The overall rate of PE diagnosis rose slowly from 0.20 % in 2016 to a peak of 0.35 % in 2021. Among those with PE, 363,584 (68.3 %) were admitted. The rate of admission declined over time from 75.6 % to 66.1 %. Among those prescribed anticoagulation, the most common medication was apixaban (40.0 %), followed by rivaroxaban (17.3 %), enoxaparin (6.1 %), warfarin (2.6 %), and dabigatran (0.4 %). Thrombolytics were administered in 4.5 % of cases, with the rate of thrombolytics peaking at 5.3 % in 2018 before lowering to 3.5 % in 2023. The overall rate of CTPA increased from 2.4 % to 5.0 %, while the rate of proportion of PEs diagnosed declined from 8.7 % to 6.4 %.
CONCLUSION: This study highlights significant shifts in the epidemiology and management of PE within the ED setting. Overall rates of PE rose, while a larger proportion were discharged. Direct oral anticoagulants have become the predominant therapy with the majority of patients receiving apixaban. Thrombolytic use occurs in a small subset and has been declining over time. CTPA rates have risen, while the overall diagnostic yield has declined.
参考来源
- Gottlieb M, Moyer E, Bernard K, et al. Epidemiology of pulmonary embolism diagnosis and management among United States emergency departments over an eight-year period. Am J Emerg Med. 2024. PMID: 39270553. doi:10.1016/j.ajem.2024.09.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。